8-K
AVANOS MEDICAL, INC. (AVNS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: November 14, 2022
(Date of earliest event reported)
Commission file number 001-36440
AVANOS MEDICAL, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 46-4987888 | |||
|---|---|---|---|---|
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||
| 5405 Windward Parkway | ||||
| Suite 100 South | ||||
| Alpharetta, | Georgia | 30004 | ||
| (Address of principal executive offices) | (Zip code) |
Registrant’s telephone number, including area code: (844) 428-2667
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered |
|---|---|---|
| Common Stock - $0.01 Par Value | AVNS | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On November 14, 2022, Avanos Medical, Inc. (the “Company”) issued a press release announcing that Sudhakar Varshney has been appointed as the Company’s Senior Vice President, Global Supply Chain and Procurement. A copy of such press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits.
The following exhibits are filed with this Current Report on Form 8-K:
| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release issued by Avanos Medical, Inc. on November 14, 2022 |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AVANOS MEDICAL, INC. | |||
|---|---|---|---|
| Date: | November 14, 2022 | By: | /s/ Mojirade James |
| Mojirade James<br>Senior Vice President and General Counsel |
Document
Exhibit 99.1
| Investor Contact: Michael Greiner |
|---|
| Avanos Medical, Inc. |
| Investor.Relations@avanos.com |
| Media Contact: Katrine Kubis |
| Avanos Medical, Inc. |
| CorporateCommunications@avanos.com |
Avanos Medical, Inc. Appoints Sudhakar Varshney as Senior Vice President, Global Supply Chain & Procurement
ALPHARETTA, Ga., Nov. 14, 2022 / PRNewswire / -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Sudhakar Varshney has been appointed senior vice president, global supply chain & procurement. In this role, Varshney will lead a multinational team of more than 2,500 employees to drive the development and execution of the Company’s supply chain capabilities worldwide.
Varshney joins Avanos from Antylia Scientific, a bioprocessing and life sciences organization, where he was senior vice president, global operations. His background includes more than 20 years in manufacturing, supply chain, engineering, quality and continuous improvement leadership roles for companies in the medical device, automotive, chemical and industrial sectors, including Hach (a division of Danaher), Haemonetics, Covidien and the Ford Motor Company.
“Given the ongoing supply chain challenges that continue to impact businesses around the world, we are very pleased to welcome Sudhakar to Avanos,” stated Joe Woody, chief executive officer. “His integrated supply chain and operations experience, and proven success in driving process improvements, will be critical as we work to transform and grow our business.”
Varshney earned a bachelor’s degree in mechanical engineering from the University of Pune (India) and a master’s of science in product development from the University of Detroit Mercy.
He will be relocating to the Atlanta area from Michigan in the near future.
About Avanos Medical, Inc.
Avanos Medical (NYSE: AVNS) is a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today’s most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries. For more information, visit www.avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.
SOURCE Avanos Medical, Inc.